Altea starts diabetes and pain skin patch trials:
This article was originally published in Clinica
Executive Summary
Altea Therapeutics has begun US clinical trials to test its noninvasive skin patch technology as a treatment for two conditions: diabetes and severe pain. The two phase I studies incorporate the Tucker, Georgia firm's proprietary PassPort system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect. The first study is testing AT1391, a daily insulin skin patch for providing continuous basal levels of insulin in diabetics. The second is assessing AT1022, a hydromorphone skin patch for the rapid and sustained delivery of a potent opiate for managing severe pain.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.